Abstract

Stability of Propranolol Hydrochloride in SyrSpend SF

Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget

Issue: Nov/Dec 2012 - Volume 16, Number 6

Page(s): 513-515

Download in electronic PDF format for $75
  • Stability of Propranolol Hydrochloride in SyrSpend SF Page 1
  • Stability of Propranolol Hydrochloride in SyrSpend SF Page 2
  • Stability of Propranolol Hydrochloride in SyrSpend SF Page 3

Note: Electronic version includes errata or revisions.

Abstract

Propranolol hydrochloride is a beta blocker used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma, and certain types of tremors. Propranolol is marketed by Wyeth (now a part of Pfizer) and AstraZeneca under the brand names Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilium, Bedranol SR (Sandoz). It is also available generically from several manufacturers. Propranolol hydrochloride is available as tablet, capsule, and oral liquid dosage forms in several strengths. Some patients are unable to tolerate oral tablets and capsules, challenging compounding pharmacies to seek alternative dosing options; namely oral solutions and suspensions. The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. The drug was compounded into a 1-mg/mL suspension using SyrSpend SF and subsequently stored in a low actinic plastic prescription bottle at room temperature conditions. Six samples were assayed at each specific time point extending to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days.

Related Keywords

  • propranolol hydrochloride
  • nonselective beta-adrenergic receptor inhibitor
  • beta blocker
  • hypertension
  • high blood pressure
  • arrhythmias
  • heart disease
  • angina
  • tremor
  • chest pain
  • oral suspension
  • stability

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • CARDIOLOGY
  • NEUROLOGY
  • STORAGE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2012
Pg. 513-515
Stability of Propranolol Hydrochloride in SyrSpend SF
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Jul/Aug 2018
Pg. 325
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2014
Pg. 330
Propranolol Hydrochloride 1-mg/mL Injection
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Mar/Apr 2022
Pg. 148
Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2015
Pg. 513
Propranolol Hydrochloride Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 504
Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet
Author(s): Allen Loyd V Jr
Sep/Oct 2022
Pg. 364-368
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Author(s): Riepl Mike
Jul/Aug 2006
Pg. 304
Propranolol Hydrochloride 1-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 194-197
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2011
Pg. 358-366
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Author(s): Zur Eyal
Nov/Dec 2007
Pg. 520-524
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Author(s): Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2011
Pg. 458-463
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Author(s): Zur Eyal
May/Jun 2006
Pg. 220
Carvedilol 1.25-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 1997
Pg. 125-127
Quantitation of Metoprolol Tartrate and Propranolol Hydrochloride in Pharmaceutical Dosage Forms: Stability of Metoprolol in an Aqueous Mixture
Author(s): Gupta Vishnu D, Maswoswe J
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
May/Jun 2020
Pg. 252-262
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Nov/Dec 2019
Pg. 494
Verapmail Hydrochloride 50 mg/mL in SyrSpend SF
Author(s): Allen Loyd V Jr
Jan/Feb 2002
Pg. 66-69
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes
Author(s): Xu Quanyun A, Trissel Lawrence A, Pham Lien